Introduction {#Sec1}
============

In patients with advanced coronary artery disease (CAD) and severely reduced LV-function, coronary artery bypass grafting (CABG) offers an important therapeutic option \[[@CR1]--[@CR4]\] Nevertheless, CABG in this specific group of patients is still associated with a high perioperative mortality that ranges from 4.6 to 20% depending on LV-function and severity of congestive heart failure \[[@CR2], [@CR4]\]. On the other hand, LV function can improve significantly after revascularization \[[@CR5]--[@CR8]\]. Clinicians face the difficulty to balance the potential benefit of surgical revascularization with the increased perioperative risk in this specific group of patients \[[@CR9]\]. In order to improve mortality, methods are sought to select patients who may benefit mostly from CABG.

The assessment of myocardial viability by nuclear imaging techniques has become an important aspect of the diagnostic and prognostic work-up of patients with ischemic cardiomyopathy \[[@CR10]--[@CR14]\]. Noninvasive imaging, such as positron emission tomography (PET), has been reported to be a useful tool for the determination of tissue viability and hence for the prediction of reversibility of regional LV dysfunction \[[@CR15]\]. PET, using nitrogen-13 (N-13) ammonia and Fluorine-18 fluorodeoxyglucose (F-18 FDG) is a well established method to further differentiate viable tissue that may benefit from revascularization from scarred myocardium \[[@CR12]--[@CR13]\].

Previous studies showed that revascularization of patients with viability results in an improvement of heart failure symptoms, and exercise capacity \[[@CR16]--[@CR17]\]. Patients selected for CABG on the basis of PET viability studies may also have fewer perioperative complications \[[@CR18]\]. A meta-analysis from 2002 including 3,088 patients suggests that the differentiation of viable from nonviable myocardium is also an important issue in the selection process between medical therapy versus myocardial revascularization in heart failure patients \[[@CR10]\]. Nevertheless, the role of viability assessment to determine suitability for revascularization is still an open question and an optimal diagnostic protocol in patients with ischemic cardiomyopathy has not yet been defined. In a recent study, Beanlands et al. \[[@CR19]\] could not demonstrate a significant reduction in cardiac events in patients with LV-dysfunction and suspected coronary disease for FDG PET-assisted management versus standard care.

The current study evaluates the hypothesis that the use of PET imaging in the decision-making process for CABG will improve postoperative patient survival. In a retrospective study, 476 consecutive patients with ischemic cardiomyopathy were analyzed who were referred for CABG between 1994 and 2004. Postoperative survival was compared in patients selected for revascularization on the basis of clinical and angiographic data alone, and patients who underwent a supplementary myocardial viability testing via PET.

Materials and methods {#Sec2}
=====================

The current study had the approval of the local Ethic Committee of the Technische Universitaet Muenchen, Munich, Germany, (2370/09). We reviewed 501 consecutive patients with ischemic cardiomyopathy (LV ejection fraction ≤0.35) who were considered candidates for CABG between 1994 and 2004. Firstly, 25 patients, who were referred from overseas, were excluded due to the impossibility of a sufficient follow-up, and 476 patients were finally included in the current study. A standardized questionnaire was sent to all patients. If no answer ensured, follow-up was obtained by telephone interview and/or further information was requested from registry offices. Thus, follow-up could be completed in 100% of the patients. Perioperative complications and mortality were recorded prospectively as part of an ongoing quality assurance program. In-hospital mortality was defined as death within 30 days after operation.

Study groups {#Sec3}
------------

Cardiac catheterization was performed in all patients to assess ventricular function and extent of coronary artery disease (CAD). Global LV-function was measured by biplane cine-angiography. The patients who were candidates for CABG were divided into two groups (Fig. [1](#Fig1){ref-type="fig"}): A Standard Care Group of 298 patients who did not have viability testing preoperatively. A second group of 178 patients underwent PET assisted management: 152 patients had sufficient viability according to PET and underwent CABG (PET-CABG), whereas 26 patients had no sufficient viability and were selected to medical treatment (*n* = 18) or transplantation (*n* = 8).Fig. 1476 candidates for CABG 1994-2004. Patients were selected for CABG on the basis of clinical presentation and angiographic data (*n* = 298, Standard Care Group) or on the basis of an additional assessment of the extent of viable tissue by PET (*n* = 178). 152 patients of the latter group underwent CABG (PET-CABG) and 26 patients were excluded from CABG because of lack of viability (PET-Alternatives) and either underwent heart transplantation (*n* = 8) or received medical treatment only (*n* = 18)

PET studies {#Sec4}
-----------

All patients without known diabetes mellitus were studied in the postprandial state after additional oral glucose loading with 50 g of glucose. Patients with known diabetes or abnormal glucose tolerance received insulin before and during the imaging sequence, according to a standardized protocol \[[@CR20]\]. After initial transmission scanning for attenuation correction, rest regional myocardial perfusion imaging with N-13 ammonia (740 MBq) was performed. After sufficient time for N-13 decay, F-18 FDG (370 MBq) was injected, and data acquisition was initiated 40 min after tracer injection. Transaxial planes were obtained using whole-body PET (Siemens CTI 951 or Siemens Exact 47). Attenuation-corrected transaxial PET images were generated from N-13 ammonia and F-18 FDG data. The images were reoriented perpendicular to the long axis of the left ventricle, after which volume-weighted polar maps were calculated from circumferential profiles of the maximal myocardial activity. In addition, the transaxial image data were realigned to generate images in short-axis, vertical and horizontal long-axis views for visual analysis \[[@CR21]\]. Regional tracer uptake of N-13 ammonia and F-18 FDG was evaluated visually, by two experienced observers who had no knowledge of the clinical and angiographic data, to estimate the extent of necrosis and viable tissue (Fig. [2](#Fig2){ref-type="fig"}). The time between viability testing and CABG was in all cases less than 3 months.Fig. 2PET-Studies and Viability Assessment. Attenuation-corrected transaxial PET images were generated from N-13 ammonia and F-18 FDG data. The images were reoriented perpendicular to the long axis of the left ventricle, after which volume-weighted polar maps were calculated from circumferential profiles of the maximal myocardial activity

Viability criteria {#Sec5}
------------------

Tissue viability by PET was assessed by the combined interpretation of perfusion and metabolism within the vascular territories of the left ventricle. The septal, anterior and anterolateral walls were considered the vascular territory of the left anterior descending coronary artery. The left circumflex coronary artery was considered to supply the lateral and posterolateral walls, whereas the vascular territory of the right coronary artery was the inferior and posterior walls. Two different viability criteria were used: (1) reduced blood flow with preserved or increased F-18 FDG uptake (mismatch); (2) normal or near-normal blood flow with normal or increased F-18 FDG uptake (normal). Reduced blood flow with reduced F-18 FDG uptake (matched defect) was used as the criterion for scar (Fig. [2](#Fig2){ref-type="fig"}). On the basis of this visual evaluation, three main criteria were used to determine whether an individual patient was a suitable candidate for CABG: (1) The presence of a "normal or mismatch" pattern in akinetic or severely hypokinetic myocardial areas supplied by a stenosed or obstructed artery was required. (2) If viable myocardium was detected in at least two different vascular territories, we considered the patient an adequate candidate for CABG, independent of the estimated target vessel size from the angiographic report. (3) A large area of scar tissue using an approximate threshold of 40% was a deciding factor against CABG. This arbitrary threshold was based on studies of acute myocardial infarction, that indicated a high incidence of cardiogenic shock in infarct areas \>40% of LV mass \[[@CR22]--[@CR24]\]. It was assumed that patients with a large infarct area are more susceptible to hemodynamic complications during CABG. The visually estimated extent of scar tissue was retrospectively confirmed by semiquantitative analysis. Scar tissue was defined as F-18 FDG uptake ≤50% of maximal uptake on "bull's eye" quantitation \[[@CR25]\]. On the basis of the PET criteria, in association with the angiographic report, 26 patients were found to be inappropriate candidates for CABG and either underwent heart transplantation (*n* = 8) or received only medical treatment (*n* = 18).

Statistical analysis {#Sec6}
--------------------

The student *t-*test for two independent samples and the chi-squared test were used for continuous and categorical outcomes, respectively, to evaluate differences between the PET-CABG and the Standard Care Group. A two-sided *P* value \<0.05 was considered statistically significant. Kaplan--Meier survival curves were calculated to estimate long-term survival; differences between groups were assessed with the log-rank test. Multiple Cox regression analysis was performed to assess the impact of the following possible risk factors simultaneously: viability, LV-function, diabetes, sex and age.

Results {#Sec7}
=======

Pre- and intraoperative patient data {#Sec8}
------------------------------------

Table [1](#Tab1){ref-type="table"} depicts the main patient characteristics of both groups. No differences were seen with regard to preoperative NYHA status, reoperation, diabetes, the presence of sinus rhythm, preoperative angina, preoperative creatinine, COPD, or prior myocardial infarction. Differences were observed regarding LV-function, age and gender. The PET-CABG exhibited a lower LV-function (PET-CABG: 26.0 ± 6.1, Standard Care Group: 28.1 ± 5.3; *P* \< 0.001; Fig. [2](#Fig2){ref-type="fig"}), a lower percentage of patients \>70 years in the PET-CABG (PET-CABG: 30.3%, Standard Care Group: 39.9%; *P* = 0.044; Table [1](#Tab1){ref-type="table"}) and the lower percentage of woman in the PET-CABG (PET-CABG: 10.5%, Standard Care Group: 17.8%;*P* = 0.043) as opposed to the Standard Care Group. 450 patients finally underwent CABG, whereas 26 patients were not selected for revascularization due to insufficient viability as defined previously. 18 patients of these group received medical treatment and 8 patients underwent heart transplantation (Fig. [1](#Fig1){ref-type="fig"}). No differences were seen between both groups regarding cardiopulmonary bypass time (PET-CABG: 103.9 min ± 33.6; Standard Care Group: 98.8 min ± 31.7; *P* = 0.128) and number of coronary anastomoses per patient (PET-CABG: 3.3 ± 1.0; Standard Care Group: 3.2 ± 0.9; *P* = 0.264) .Table 1Pre- and intraoperative dataClinical parameterPET-CABG (*n* = 152)Standard Care Group (*n* = 298)*P*LVEF26.0 ± 6.128.1 ± 5.3\< 0.01Age64.0 ± 9.866.2 ± 9.30.02Age \>70 years46 (30.3%)119 (39.9%)0.04Female gender16 (10.5%)53 (17.8%)0.04NYHA III + IV136 (89.5%)279 (93.6%)0.12Angina104 (68.4%)237 (79.5%)0.12Prior myocardial infarction107 (70.4%)208 (69.8%)0.74Chronic obstructive pulmonary disease17 (11.2%)33 (11.1%)0.79Preoperative creatinine (mg/dl)1.29 ± 0.51.34 ± 0.80.91Prior cardiac surgery11 (7.2%)23 (7.7%)0.86Diabetes60 (39.5%)111 (37.2%)0.82Sinus rhythm135 (88.8%)255 (85.6%)0.34Cardiopulmonary bypass (minutes)103.9 ± 33.698.8 ± 31.70.128No. anastomoses per patient3.3 ± 1.03.2 ± 0.90.264

Follow-up {#Sec9}
---------

Mean follow-up was 3.8 years ± 3.02, range from 2 days to 11.07 years (group A: 4.9 ± 2.9, range from 1 day to 10.1 years; group B: 3.3 ± 2.9, range 0.002--11.1 years; PET-Alternatives: 3.16 ± 3.1, range from 0.02 to 10.9 years) (Fig. [1](#Fig1){ref-type="fig"}). Survival analysis was calculated according to Kaplan--Meier and a log-rank test was performed (Fig. [1](#Fig1){ref-type="fig"}). The log-rank test between the PET and the Standard Care Group showed also significant difference (p = 0.0052). There were two in hospital deaths in the PET-CABG (1.3%) and 30 (10.1%) in the Standard Care Group (*P* = 0.018). The survival rate after 1, 5 and 10 years were in the PET-CABG 92.0, 73.3 and 54.2% and in the Standard Care Group 88.9, 62.2 and 35.5%, respectively (*P* = 0.005). In the group of PET-Alternatives, survival rate was 61.5% (0.8 years), and 29.2% (4.8 years). Cox-regression analysis revealed an influence of preoperative viability assessment via PET (*P* = 0.008), of preoperative LV-function (*P* = 0.017), and age \>70 (*P* = 0.016) on long-term survival. Diabetes (*P* = 0.072) and female gender (*P* = 0.085) had no significant influence (Table [2](#Tab2){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}).Table 2Risk assessment for long-term survival (Cox)Estimated regression coefficientHazard ratio*P*Viability0.231.26\<0.01LVEF−0.200.820.02Diabetes0.151.160.07Female0.131.140.09Age \>700.201.220.02Fig. 3Cumulative survival after CABG

Discussion {#Sec10}
==========

Although surgical revascularization remains an important therapeutic option in ischemic cardiomyopathy, these patients face high perioperative mortality when undergoing CABG that ranges from 4.6 to 20% depending on LV-function, comorbidities and severity of congestive heart failure \[[@CR2], [@CR4], [@CR26]\]. Previous studies found a benefit from revascularization for patients with defined viability by a non-invasive technique, so that preoperative patient selection by viability testing has become an issue \[[@CR10], [@CR11], [@CR21], [@CR27]--[@CR29]\].

To assess myocardial viability, different diagnostic methods are currently performed, i.e. FDG/PET, MRI, SPECT and echocardiography whereas FDG/PET is considered the gold-standard due to its ability to differentiate dysfunctional but viable myocardium (hibernating myocardium) from scar formation and normal myocardium \[[@CR14], [@CR30]\]. In a multi-centre study including 157 patients, Gerber et al. \[[@CR31]\] showed a high sensitivity and moderate specificity of FDG/PET to predict improvement of cardiac function after coronary revascularization. The improvement of LV-function after revascularization seems to be directly related to the number of dysfunctional but viable segments, i. e. the mass of viable tissue \[[@CR32]--[@CR35]\]. Furthermore, Tarakji et al. \[[@CR36]\] described a strong association between early revascularization and survival in a large series of 765 patients who underwent comprehensive PET imaging.

A meta-analysis from 2002 included 3,088 patients published in studies examining survival with revascularization versus medical therapy after myocardial viability testing in patients with ischemic cardiomyopathy \[[@CR10]\]. Non-invasive imaging techniques included thallium perfusion imaging, FDG/PET, and dobutamine echocardiography. Viability was interpreted as "present" or "absent" based on individual study definitions. The authors found a strong association between myocardial viability on noninvasive testing and improved survival after revascularization in patients with ischemic cardiomyopathy. Furthermore, it was suggested that the differentiation of viable from nonviable myocardium could be crucial in the selection process between medical therapy versus myocardial revascularization.

Nevertheless, the role of viability assessment to determine suitability for revascularization is still an open question and an optimal diagnostic protocol in patients with ischemic cardiomyopathy has not yet been defined. Recently, in the PARR-2 study (Positron emission tomography and recovery following revascularization), Beanlands et al. included patients with ischemic cardiomyopathy and randomized the patients to management assisted by FDG PET (*n* = 218) or standard care (*n* = 212). The study found a reduction of adverse cardiac events of 36% in the standard care arm versus 30% in the PET-assisted arm that did not reach statistical significance \[[@CR19]\]. This study has been criticized for the fact, that 25% patients with PET-indicated revascularization did not have it done \[[@CR37]\]. In the subgroup of patients who adhered to PET recommendations regarding revascularization, however, significant survival benefits were observed. These findings are supported by the current study, in which every patient with sufficient viability in the PET-assisted group underwent CABG and exhibited significant better mortality rates after revascularization.

The concept of a preoperative PET-based selection of patients who benefit mostly from CABG was examined by Haas et al. \[[@CR18]\] who found a significant reduction in perioperative mortality in patient with defined viability. Subsequent studies indicate that dysfunctional regions with normal perfusion are more common than mismatch, have less associated tissue injury and are more likely to demonstrate complete recovers than mismatch segments (31 vs. 18%, respectively) \[[@CR38]--[@CR39]\].

The key finding of the present study was the significant reduction of the 30-day mortality in the PET-CABG group with 1.3 versus 10.3% in the Standard Care group. Despite the improvement of hospital mortality after CABG in the last years, the observed early mortality rate of 1.3% in the PET-CABG group is lower than current reports by the STICH (Surgical Treatment for Ischemic Heart Failure) study \[[@CR3]\] or the study by Nardi et al. \[[@CR26]\], that reported a hospital mortality of 5 and 5.3%, respectively. The early survival benefit of the PET-CABG persists in the long-term as reflected by the superior survival of the PET-CABG over a 10 year follow-up.

A preoperative selection protocol, based on myocardial viability testing via PET identifies patients who can undergo CABG with a risk profile that is comparable to CABG in patients with normal LV-function. The Standard Care Group did not undergo a selection process via PET, and presumably patients with greater unrecognized extent of scar tissue were not excluded.

The selection process in the present study leads to a proper identification of patients with a lower risk profile when undergoing CABG. Statistical analysis revealed the selection process itself as a significant prognostic factor for postoperative survival (Table [2](#Tab2){ref-type="table"}). FDG/PET offers unique information beside clinical and angiographic date that leads to improved patient selection, which subsequently results in improved postoperative recovery with a low early mortality and superior long-term survival after CABG. An important limitation of this study is its retrospective design. The preoperative scheduling for viability testing was based on an intention-to-treat basis, but not in a prospective, randomized manner, so that a potential bias cannot be totally excluded.

Previous studies have addressed the issue of patient selection for revascularization in ischemic cardiomyopathy due to the high perioperative risk. Nevertheless, former studies lack long-term follow-up as well as sufficient sample size to analyze potential benefits of viability testing prior revascularization. Additional arguments have been discussed: According to subgroup analysis of the PARR-2 study, the adherence to PET recommendations remains crucial \[[@CR19]\]. In the PET-assisted group of the current study, PET recommendations were consequently followed in all cases.

Timing of revascularization has become another issue of recent research \[[@CR36]\], suggesting a benefit from early revascularization. In the current study, patients were already candidates for CABG when viability testing was performed and subsequently every patient of the PET-assisted group underwent surgery in less than 3 month time after PET. Furthermore, the results of the current study are in line with the PARR-1study that found the amount of scar detected by FDG-PET as a significant independent predictor of LV function recovery after revascularization \[[@CR40]\].

The main limitation of the current study is its retrospective design. The study included patients with severe reduction of LV function who were referred for revascularization. Limited availability of PET and outside referral prohibited prospective randomization of patients in this study. Although a randomization protocol would have been ideal, careful retrospective analysis of risk factors was performed in both groups to identify any selection bias. The decision for an additional viability testing was made by the responsible surgeon. Both groups suffer equally from angina and are in NYHA III + IV (Table [1](#Tab1){ref-type="table"}). Important risk factors for perioperative mortality, such as preoperative renal function, diabetes, prior myocardial infarction, chronic obstructive pulmonary disease, prior cardiac surgery or diabetes are comparable in both groups (Table [1](#Tab1){ref-type="table"}). Furthermore, intraoperative parameters like cardiopulmonary bypass time or the number of anastomoses per patient did not differ between the two groups. Only small differences between the two groups were seen in LVEF, age, and gender (Table [1](#Tab1){ref-type="table"}).

The present study did not compare FDG-PET with other imaging modalities for detection of viable myocardium. Further studies are necessary to determine whether the same results may be obtained with conventional scintigraphic techniques, such as thallium-201 imaging, magnetic resonance imaging or low dose dobutamine echocardiography.

Nevertheless, the cut-off point of 40% of scar tissue for the indication for CABG, which was applied in the present study, represents an arbitrary threshold. This arbitrary threshold was based on studies of acute myocardial infarction that indicated a higher incidence of cardiogenic shock in infarct areas averaging 37, 43 and 51% of LV mass \[[@CR22]--[@CR24]\] which may indicate an irreversible condition. Yoshida et al. \[[@CR24]\] showed that the size of the infarct area and viability in arterial zones at risk assessed by PET are good prognostic markers for mortality. In their study, 6 of 35 patients had an infarct size between 39 and 77%, as determined by quantitative PET measurements. Four of these patients died within a 3-year period, three of them after revascularization.

As the present study showed, the criterion of scar extent alone is not sufficient for the selection process in some patients. Four patients in the PET-CABG exhibited a scar tissue area ≥40%. However, in these patients the other main viability criteria and the angiographic report supported the decision, that these patients were adequate candidates for CABG. Two of the patients are still alive (follow-up time: 6.7 and 7.7 years). In both patients, PET revealed high percentages of viable myocardium: 40--45% scar, 52--60% viable myocardium and 0--3% mismatch. A third patient died 8 months after surgery (PET: 46% scar, 5% mismatch and 49% viable myocardium), and the fourth patient died 3.9 years after CABG (PET: 43% scar, 10% mismatch, 47% viable myocardium). These findings underscore the complexity of decision making in this specific group of patients. Nevertheless, only four patients of 178 patients (2.24%), who underwent preoperative PET management, did not totally apply to the exclusion criterion by PET. Therefore, we suggest that in patients with a scar tissue area of around 40%, the 40% cut-off point should not be strictly applied but appreciated in request to the other viability criteria as well as angiographic results.

Conclusions {#Sec11}
===========

In ischemic cardiomyopathy, patient selection by preoperative viability testing via PET leads to a significant reduction of perioperative mortality rates after surgical revascularization. This survival benefit persists in the long-term. Prospective, randomized are necessary to further evaluate the impact of preoperative viability assessment in this high risk group of patients.
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